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Objective. The number of confirmed rheumatoid
arthritis (RA) loci currently stands at 32, but many lines
of evidence indicate that expansion of existing genome-
wide association studies (GWAS) enhances the power to
detect additional loci. This study was undertaken to
extend our previous RA GWAS in a UK cohort, adding
more independent RA cases and healthy controls, with
the aim of detecting novel association signals for sus-
ceptibility to RA in a homogeneous UK cohort.
Methods. A total of 3,223 UK RA cases and 5,272
UK controls were available for association analyses,
with the extension adding 1,361 cases and 2,334 controls
to the original GWAS data set. The genotype data for all
RA cases were imputed using the Impute program
version 2. After stringent quality control thresholds
were applied, 3,034 cases and 5,271 controls (1,831,729
single-nucleotide polymorphisms [SNPs]) were avail-
able for analysis. Association testing was performed
using Plink software.
Results. The analyses indicated a suggestive as-
sociation with susceptibility to RA (P < 0.0001) for 6
novel RA loci that have been previously found to be
associated with other autoimmune diseases; these 6
SNPs were genotyped in independent samples. Two of
the associated loci were validated, one of which was
associated with RA at genome-wide levels of significance
in the combined analysis, identifying a novel RA locus at
22q12 (P  6.9  109). In addition, most of the
previously known RA susceptibility loci were confirmed
to be associated with RA, and for 16 of the loci, the
strength of the association was increased.
Conclusion. This study identified a new RA locus
mapping to 22q12. These results support the notion that
increasing the power of GWAS enhances novel gene
discovery.
Understanding the genetic component of suscep-
tibility to rheumatoid arthritis (RA) will increase our
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knowledge of the disease process and has the potential
to inform new approaches to disease management. For
example, the identification of disease-associated genetic
variations, which are presumed to cause modified im-
mune responses and precede the onset of disease symp-
toms, could inform stratification of patients into more
phenotypically homogeneous subgroups and provide
testable hypotheses regarding response to treatment.
The use of genome-wide association studies (GWAS)
has been remarkably successful in locating novel genetic
loci associated with RA, and there are now more than 30
gene regions that have been confirmed as RA suscepti-
bility loci, but, in total, they account for fewer than 50%
of the total genetic heritability (1,2). It is likely that there
are more common variants of small effect size that could
be identified by increasing the power of the GWAS
through the use of larger sample sizes. Indeed, this
approach has been used successfully in a number of
autoimmune diseases, such as type 1 diabetes (3) and
inflammatory bowel disease (4,5), resulting in a more
complete picture of the genetic background.
In the present study, we used the data set from an
RA GWAS in the UK (6) and increased the sample sizes
of the RA cases and healthy controls by 75% and 80%,
respectively. With this extended data set, together with
the data obtained in a validation study of the UK cohort,
we were able to discover potential novel RA risk loci in
the UK population. This study constitutes the largest
UK-only GWAS to date, and the results will enhance the
power to investigate whether population heterogeneity
exists, i.e., whether different genes are associated with
RA in different populations.
PATIENTS AND METHODS
Genotype data were available for 1,862 RA cases and
2,938 controls from the original Wellcome Trust Case Control
Table 1. Previously confirmed rheumatoid arthritis (RA) loci association results in the original WTCCC association analysis and the expanded UK
RA GWAS*
Chr. SNP Gene
WTCCC study Expanded UK RA GWAS
Proxy P OR (95% CI) Proxy P OR (95% CI)
1 rs3890745 TNFRSF14 8.47  106 0.82 (0.75–0.89) 1.43 106 0.85 (0.79–0.91)
1 rs2476601 PTPN22 rs6679677 2.60 1025 1.90 (1.68–2.15) 4.87 1033 1.77 (1.61–1.95)
1 rs11586238 CD2, CD58 4.13  104 1.19 (1.08–1.31) rs4271251 6.47 103 1.11 (1.03–1.19)
1 rs12746613 FCGR2A 0.04 1.14 (1.01–1.29) 0.03 1.11 (1.01–1.22)
1 rs10919563 PTPRC 0.003 0.82 (0.72–0.94) 7.18 105 0.82 (0.74–0.9)
2 rs13031237 REL None rs13031721 0.29 1.04 (0.97–1.11)
2 rs934734 SPRED2 0.10 0.93 (0.86–1.01) 0.11 0.95 (0.89–1.01)
2 rs10865035 AFF3 rs9653442 5.48 104 1.16 (1.07–1.26) rs1160542 1.37 105 1.15 (1.08–1.23)
2 rs7574865 STAT4 rs11893432 0.02 1.13 (1.02–1.25) rs10181656 6.64 104 1.14 (1.06–1.23)
2 rs1980422 CD28 4.80  103 1.15 (1.04–1.26) 1.75 104 1.15 (1.07–1.24)
2 rs3087243 CTLA4 0.09 0.93 (0.86–1.01) 0.02 0.92 (0.87–0.99)
3 rs13315591 PXK 0.20 1.10 (0.95–1.26) None
4 rs874040 RBPJ None rs6448432 3.88  107 1.19 (1.11–1.28)
4 rs6822844 IL2, IL21 None rs62322744 6.42  103 1.18 (1.05–1.32)
5 rs6859219 ANKRD55,
IL6ST
5.5  106 0.78 (0.70–0.87) None
5 rs26232 C5orf30 rs556560 2.46 104 0.85 (0.78–0.93) rs556560 9.64 105 0.88 (0.82–0.94)
6 rs6910071 HLA–DRB1 rs6457617 3.49 1079 0.44 (0.40–0.48) rs3763309 1.50 10124 2.3 (2.14–2.46)
6 rs548234 PRDM1 0.01 1.12 (1.02–1.22) 1.24 103 1.12 (1.04–1.19)
6 rs6920220 TNFAIP3 6.11  106 1.25 (1.13–1.37) 3.11 108 1.23 (1.14–1.32)
6 rs394581 TAGAP 5.86  103 0.88 (0.80–0.96) None
6 rs3093023 CCR6 rs6907666 0.05 1.09 (1–1.18) rs3093024 1.88 103 1.11 (1.04–1.18)
7 rs10488631 IRF5 rs12531711 0.03 1.16 (1.02–1.31) 3.10 103 1.16 (1.05–1.28)
8 rs2736340 BLK 8.01  103 1.14 (1.03–1.25) 0.05 1.07 (1–1.15)
9 rs2812378 CCL21 1.14  103 1.15 (1.06-1.26) None
9 rs3761847 TRAF1, C5 0.80 0.99 (0.91–1.07) 0.19 1.04 (0.98–1.11)
10 rs2104286 IL2RA 7.06  106 0.81 (0.73–0.89) 1.46 106 0.84 (0.78–0.9)
10 rs4750316 PRKCQ 5.22  105 0.80 (0.72–0.89) 1.55 104 0.85 (0.78–0.93)
11 rs540386 TRAF6 0.04 0.88 (0.77–0.99) rs1046864 0.01 0.89 (0.8–0.98)
12 rs1678542 KIF5A 2.81  105 0.83 (0.76–0.91) 9.75 108 0.83 (0.78–0.89)
20 rs4810485 CD40 0.07 0.91 (0.83–1.01) rs1569723 0.22 0.95 (0.89–1.03)
22 rs3218253 IL2RB 1.88  104 1.19 (1.09–1.31) 2.51 104 1.15 (1.07–1.23)
* WTCCC Wellcome Trust Case Control Consortium; GWAS  genome-wide association study; Chr.  chromosome; SNP  single-nucleotide
polymorphism; OR  odds ratio; 95% CI  95% confidence interval.
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Consortium (WTCCC) study (6); these genotypes were ob-
tained using the Affymetrix 500K array. Together with this
data set, we added GWAS genotype data for a further 2,334
UK controls and 1,361 UK RA cases (sample call rate 95%).
The additional samples were from 5 different studies, with
genotypes obtained using a range of GWAS arrays. Members
of the WTCCC, UK Rheumatoid Arthritis Genetics Group,
and Biologics in Rheumatoid Arthritis Genetics and Genomics
Study Syndicate Consortiums and details on the platforms used
are given in the Supplementary Materials and Supplementary
Table 1, available on the Arthritis & Rheumatology web site at
http://onlinelibrary.wiley.com/doi/10.1002/art.38196/abstract.
Since each GWAS array contains different single-
nucleotide polymorphisms (SNPs), the first stage of the cur-
rent study was to impute genotypes to generate data for a
common set of SNPs, thus allowing combined analysis of the
data from the 5 different studies. The genotypes of the patients
in each RA case cohort were imputed using the Impute
program (version 2) (7), based on 2 reference panels, the 1000
Genomes Project pilot data and HapMap3. The genotypes of
control subjects were imputed using the same 1000 Genomes
Project reference panel, with imputation performed using
MaCH software (8). Stringent quality control (QC) thresholds
were applied to individual cohorts and then to the merged data
set (see Supplementary Figure 1, available on the Arthritis &
Rheumatology web site at http://onlinelibrary.wiley.com/doi/
10.1002/art.38196/abstract). Self-reported information on each
subject’s ethnicity was used to exclude non-Caucasians from
the analyses.
Identity-by-descent analysis was performed in Plink
statistical software. Pairs of samples with genome identity
(pi-hat values) greater than 0.9 were reported to be duplicate
samples, and those with pi-hat values greater than 0.2 were
considered to be closely related. Case and control genotype
data were compared using logistic regression, performed in
Plink (9). Novel SNPs not previously found to be associated
with RA in the UK population were selected for validation if
the association P value was less than 0.0001, and if the region
had been previously found to be associated with another
autoimmune disease. The SNPs satisfying these criteria were
genotyped in independent UK samples (4,726 cases and 2,625
controls), using Sequenom technology. Additional control data
were available using non–autoimmune disease cases (n 
7,670) from the WTCCC study (6).
A regional association plot for the 22q12 locus was
created using LocusZoom (http://csg.sph.umich.edu/
locuszoom/). Bioinformatics analysis was performed using pub-
licly available functional annotation files (http://genome.
ucsc.edu/) and our own custom query SQL-code (Assimilator;
available at http://assimilator.mhs.manchester.ac.uk/cgi-bin/
assimilator.pl) (10).
RESULTS
Forty-two duplicate samples were removed after
identity-by-descent analysis. There were 14 pairs of
individual samples with pi-hat values greater than 0.2,
and thus 1 sample from each pair was removed due to
possible relatedness. A total of 1,831,729 SNPs passed
QC and were included in the association analysis. In the
expanded GWAS, 3,034 RA cases and 5,271 controls
passed QC.
The genetic inflation factor lambda (GC) was
1.06, implying that there was a low possibility of false-
positive associations attributable to population stratifi-
cation, genotyping errors, or other artifacts. For most of
the previously known RA susceptibility loci (2), we
confirmed their association with RA in the present study
(Table 1). Interestingly, when compared to the original
WTCCC study (6), the extended RA GWAS showed
that the strength of the association with RA susceptibil-
ity was increased for 16 of the loci in the UK population
(TNFAIP3, STAT4, PTPN22, HLA–DRB1, PTPRC, IL2/
IL21, C5orf30, CD247, CTLA4, RBPJ, PRDM1, CCR6,
IRF5, TRAF6, KIF5A, and CD28). For example, the
association of TNFAIP3 with RA risk reached genome-
wide levels of significance in this expansion of the
WTCCC analysis, and the robustly validated locus
STAT4, for which no significant association had been
found in the original WTCCC study, was found to be
associated with RA in the present study (Figure 1).
Similar to the findings in the original WTCCC
study, some of the known RA loci (CD40, REL,
SPRED2, BLK, and TRAF1/C5) were not found to have
an association with RA in the present study. Finally, no
proxies were available for 4 of the known RA loci.
Six of the SNPs with suggestive evidence of
association with RA in the present study and with
additional evidence of association in other studies were
selected for validation analysis (Table 2). Evidence of an
association with susceptibility to RA was found for
rs1043099 (on chromosome 22q12) in this validation
study (P  2.7  103), and the association exceeded
Figure 1. Manhattan plots showing P values for genetic association
with rheumatoid arthritis (RA) in the original Wellcome Trust Case
Control Consortium genome-wide association study (GWAS) (a) and
the expanded UK GWAS (b). Panels are truncated at alog10 P value
of 35. Single-nucleotide polymorphisms having an association with RA
at genome-wide levels of significance are shown above the horizontal
red line.
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genome-wide significance thresholds in the combined
analysis (P  6.9  109) (Figure 2). A SNP on
chromosome 11, near CXCR5 and in strong linkage
disequilibrium (LD) (r2  0.9) with a SNP previously
associated with RA at genome-wide significance levels
(11), was also associated with RA in the validation
cohort (P  0.02), and there was suggestive evidence of
association in the combined analysis (P  1.8  105).
In further analyses, we interrogated publicly
available functional annotation data (10,12) and found
evidence to indicate that rs1043099 and its correlated
SNPs (r2  0.8) may have regulatory activity in RA.
First, the SNP alleles were found to be associated with
expression levels of the SF3A1 gene (which encodes
subunit 1 of the splicing factor 3a protein complex)
(http://eqtl.uchicago.edu/cgi-bin/gbrowse/eqtl/) (Man-
gravite LM, et al: unpublished observations). Second,
several of the SNPs map to sites of transcription factor
binding, histone modification, and open chromatin (Ta-
ble 3), suggesting that these SNPs could influence gene
transcription.
We then stratified the expanded UK GWAS and
validation data sets according to the presence or absence
of anti–cyclic citrullinated peptide (anti-CCP) antibod-
ies in RA patients. The proportion of anti-CCP–positive
RA patients in the original WTCCC study, expanded
UK GWAS, and validation study was 79%, 73.5%, and
67%, respectively. SNP rs1043099 was significantly asso-
ciated with both anti-CCP–positive RA and anti-CCP–
negative RA. In contrast, SNP rs6421571 was associated
with anti-CCP–positive RA only (see Supplementary
Table 2, available on the Arthritis & Rheumatology web
site at http://onlinelibrary.wiley.com/doi/10.1002/
art.38196/abstract). Similar results were obtained when
patients were stratified by the presence of rheumatoid
Figure 2. Regional plot of association with rheumatoid arthritis (RA)
at chromosome 22q12. The P values for association (log10 values) of
each single-nucleotide polymorphism (SNP) are plotted against their
physical position on chromosome 22 (top panel). Estimated recombi-
nation rates from the 1000 Genomes Project population show the local
linkage disequilibrium (LD) structure (middle panel). Different colors
indicate the LD of each SNP with rs1043099, based on pairwise r2
values from the 1000 Genomes Project. Gene annotations are shown in
the lower panel.
Table 3. Potential regulatory role of the rheumatoid arthritis–associated single-nucleotide polymorphism (SNP) rs1043099 and its proxies*
SNP
Relative
location Gene
Transcribed
region
Histone
modifications TFBS
DNase I
HS FAIRE
CTCF
binding eQTL
rs2108093 3 GATSL3 Yes Yes Yes Yes Yes
rs1043099 Exonic, 3-UTR GATSL3 Yes Yes Yes Yes Yes
rs4823085 5 GATSL3 Yes Yes Yes Yes Yes Yes Yes
rs929454 Intronic TBC1D10A Yes Yes Yes Yes Yes
rs4820831 Intronic TBC1D10A Yes Yes Yes Yes Yes Yes
rs740219 Intronic TBC1D10A Yes Yes Yes Yes Yes
rs5753071 3 SF3A1 Yes Yes Yes Yes Yes
rs10376 Exonic, 3-UTR SF3A1 Yes Yes Yes Yes Yes
rs2041199 Intronic SF3A1 Yes Yes Yes Yes
rs4339043 Intronic SF3A1 Yes Yes Yes Yes Yes
rs5749066 Intronic SF3A1 Yes Yes Yes Yes Yes
rs5753080 Intronic SF3A1 Yes Yes Yes
rs10427610 Intronic SF3A1 Yes Yes Yes Yes Yes Yes
rs4820008 Intronic SF3A1 Yes Yes Yes
rs737950 Intronic CCDC157 Yes Yes Yes
rs5749078 Intronic CCDC157 Yes Yes Yes Yes
rs9619104 3 CCDC157 Yes Yes Yes Yes
* Proxies of rs1043099 were correlated at r2  0.8. Results are the summary output from the Assimilator bioinformatics analysis. TFBS 
transcription factor binding site; HS  hypersensitive sites; FAIRE  open chromatin by formaldehyde-assisted isolation of regulatory elements;
CTCF  CCCTC binding factor; eQTL  expression quantitative trait loci; 3-UTR  3-untranslated region.
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factor (see Supplementary Table 3, available on the
Arthritis & Rheumatology web site at http://
onlinelibrary.wiley.com/doi/10.1002/art.38196/abstract).
DISCUSSION
In this study, we discovered a new RA risk locus
on chromosome 22q12, rs1043099, for which the associ-
ation with susceptibility to RA reached genome-wide
levels of significance (combined P  6.9  109). This
locus has previously been associated with other auto-
immune diseases, including type 1 diabetes (3) and
inflammatory bowel disease (5,13). The SNP lies within
a gene of unknown function, GATSL3. It will be inter-
esting to better fine-map this region in RA, as well as in
other autoimmune diseases, to help determine which
gene is causal. Using bioinformatics analysis, we showed
that rs1043099 and its correlated SNPs have potential
regulatory activity. Interestingly, evidence suggests that
these SNPs act as expression quantitative trait loci for
the SF3A1 gene. SFA1 is involved in messenger RNA
splicing, but the particular role that this gene might have
in the pathogenesis of RA has not yet been explored.
Further functional studies will be required to determine
which of the SNPs is causal and to elucidate the mech-
anisms of action of each SNP.
Of the remaining SNPs tested in the validation
samples, evidence of increased strength of the associa-
tion with susceptibility to RA was found only for
rs6421571 on chromosome 11q23 (combined P  1.8 
105). This SNP maps 5 to the CXCR5 gene, which is a
chemokine involved in B cell migration and localization,
and has previously been associated with primary biliary
cirrhosis (14). Different SNPs in the same region have
been found to be associated with multiple sclerosis (15)
and RA (11). The SNP identified as being significantly
associated with RA and celiac disease in a combined
analysis, rs10892279, is adjacent to the gene DDX6, and
although it is 130 kb from rs6421571, the 2 SNPs are
strongly correlated (r2  0.9). Therefore, which of these
2 strong candidate genes will ultimately be found to be
causal requires further fine-mapping and functional
studies.
The added power provided by this study strength-
ens the evidence for an association with RA for 16 loci
that were already confirmed to be associated with RA in
the UK population (2). The most striking findings
supporting an association with RA within the UK pop-
ulation, as evidenced by an increase in the significance of
the association from the original WTCCC study to the
expanded GWAS, were seen for the loci at PTPRC
(increasing from P  0.003 to P  7  105), TNFAIP3
(increasing from P  6  106 to P  3  108), and
KIF5A (increasing from P  2  105 to P  9  108).
RBPJ, not available for analysis in the original WTCCC
study, showed evidence of a strong association with RA
in this expanded GWAS (P  3  107).
There was little evidence of an association with
other previously confirmed RA loci in this expanded UK
data set, including FCGR2A, REL, SPRED2, CTLA4,
BLK, TRAF1, and CD40. This could be attributed to a
number of factors, but the most likely explanation is that
the current study was underpowered to detect such
associations. Although we performed a relatively large
discovery study, the power to detect all of the associa-
tions was limited (average power across SNPs with a
minor allele frequency 5% was 47% for an odds ratio
[OR] of 1.1, and 90% for an OR of 1.2), and
therefore failure to detect a signal could simply be the
result of stochastic variations leading to a false-negative
result. Indeed, it is well established that even the most
strongly associated signals across multiple diseases are
not found to be consistently associated in all cohorts,
and often an accumulation of evidence is required in
many thousands of samples. In this regard, a recent
meta-analysis failed to detect the association between
the 22q12 locus and RA that we identified in the current
study (for rs929454, P  0.63, r2  0.91 for LD with
rs1043099) (2).
Interestingly, most of the confirmed RA loci for
which we did not find any association with RA in the
expanded UK data set (FCGR2A, REL, SPRED2,
CTLA4, BLK, TRAF1, and CD40) were found to have an
association with anti-CCP–positive RA, but not anti-
CCP–negative RA, in a recent study, which was the
largest anti-CCP–stratified RA sample size studied to
date (16). We found very modest evidence of association
with anti-CCP–positive RA for only 2 of the above-
mentioned variants (P 0.03 for FCGR2A, and P 0.03
for BLK), and therefore it is likely that the present study
was underpowered to detect serotype-specific effects at
these RA loci.
This study has added to the argument that in-
creasing the size, and consequently the power, of RA
GWAS can prove fruitful in the discovery of novel
genes. Increasing the number of known disease loci will
facilitate the estimation of disease risk, potentially al-
lowing early intervention in high-risk groups, possibly
informing prognosis, and, ultimately, aiding in the dis-
covery of novel targets for pharmacologic therapy. Fu-
ture work will involve adding this new extended UK data
to existing meta-analyses of RA case data with the aim of
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expanding our knowledge of the common genetic vari-
ants predisposing to RA.
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